WeVote
Log In

Bill

Bill

HR 8143

Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026.

119th Congress Introduced by Jake Auchincloss and 2 co-sponsors

Bill expands Medicare's authority to negotiate lower drug prices directly with pharmaceutical manufacturers, reducing senior out-of-pocket medication costs.

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 8143

Legislative bill overview

HR 8143 aims to expand Medicare's ability to negotiate drug prices directly with pharmaceutical manufacturers and would lower out-of-pocket costs for seniors on prescription medications. The bill addresses rising medication expenses for elderly Americans by allowing Medicare greater pricing power in the pharmaceutical market, similar to negotiation authority already granted to the Veterans Health Administration.

Why is this important

Seniors spend a significant portion of their healthcare budgets on prescription drugs, with many rationing or skipping medications due to cost. This bill could substantially reduce what Medicare beneficiaries pay for medications, potentially saving billions in out-of-pocket expenses across the senior population, though it would likely affect pharmaceutical company revenues and drug development incentives.

Potential points of contention

  • Drug innovation concerns: Pharmaceutical companies argue that price controls reduce profit incentives for developing new treatments, potentially slowing innovation and future drug availability
  • Implementation complexity: Determining fair "negotiated" prices requires complex economic analysis and could create disputes over which drugs qualify and what constitutes reasonable pricing
  • Market dynamics: Critics worry aggressive price negotiation could limit drug availability, reduce competition, or cause manufacturers to withdraw certain medications from the U.S. market

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.